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Anti-inflammatory Targets for the 
Treatment of Reperfusion injury  
in Stroke
Atsushi Mizuma and Midori A. Yenari*
Department of Neurology, University of California, San Francisco and Veterans Affairs Medical Center, San Francisco, CA, 
United States
While the mainstay of acute stroke treatment includes revascularization via recombinant 
tissue plasminogen activator or mechanical thrombectomy, only a minority of stroke 
patients are eligible for treatment, as delayed treatment can lead to worsened outcome. 
This worsened outcome at the experimental level has been attributed to an entity known 
as reperfusion injury (R/I). R/I is occurred when revascularization is delayed after critical 
brain and vascular injury has occurred, so that when oxygenated blood is restored, 
ischemic damage is increased, rather than decreased. R/I can increase lesion size and 
also worsen blood barrier breakdown and lead to brain edema and hemorrhage. A major 
mechanism underlying R/I is that of poststroke inflammation. The poststroke immune 
response consists of the aberrant activation of glial cell, infiltration of peripheral leukocytes, 
and the release of damage-associated molecular pattern (DAMP) molecules elaborated 
by ischemic cells of the brain. Inflammatory mediators involved in this response include 
cytokines, chemokines, adhesion molecules, and several immune molecule effectors 
such as matrix metalloproteinases-9, inducible nitric oxide synthase, nitric oxide, and 
reactive oxygen species. Several experimental studies over the years have characterized 
these molecules and have shown that their inhibition improves neurological outcome. 
Yet, numerous clinical studies failed to demonstrate any positive outcomes in stroke 
patients. However, many of these clinical trials were carried out before the routine use 
of revascularization therapies. In this review, we cover mechanisms of inflammation 
involved in R/I, therapeutic targets, and relevant experimental and clinical studies, which 
might stimulate renewed interest in designing clinical trials to specifically target R/I. We 
propose that by targeting anti-inflammatory targets in R/I as a combined therapy, it 
may be possible to further improve outcomes from pharmacological thrombolysis or 
mechanical thrombectomy.
Keywords: reperfusion injury, postischemic inflammation, microglia, hyperglycemia, ischemic stroke, 
revascularization, tissue plasminogen activator, endovascular treatment
iNTRODUCTiON
Treatment of acute ischemic stroke has largely been limited to strategies to restore blood flow. 
Pharmacological recanalization, particularly tissue plasminogen activator (tPA) has been the 
mainstay for acute treatment for the past 20 years (1, 2), but in recent years, several studies have 
shown that mechanical embolectomy is also effective (3). However, the short time frame for safe 
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intervention is still limited even considering recent studies that 
suggest additional criteria for treating “wake up stroke” (4) and 
longer time windows of up to 24 h for embolectomy (5). It is still 
estimated that less than 10% of all acute stroke patients benefit 
from reperfusion strategies. One of the reasons for such a short 
time window is that intervention beyond this time window actu-
ally increases risk and leads to worsened outcome (6). If these 
recanalization therapies are applied too late, there is an increased 
risk of cerebral hemorrhage, which can sometimes prove fatal (7). 
The mechanism of cerebral hemorrhage complicating ischemic 
stroke is a consequence of a phenomenon known as “reperfusion 
injury” (R/I) (8) to which inflammation is a major contributing 
cause.
While the restoration of cerebral blood flow (CBF) is a major 
goal of acute stroke treatment, it can also lead to more exten-
sive brain tissue damage in the adjacent penumbral territory 
(9). If recanalization is carried out after a critical time window, 
the sudden restoration of oxygenated blood into ischemically 
compromised brain tissue may overwhelm already compromised 
endogenous antioxidant systems and damaged vascular endothe-
lia leading to brain edema and extravasation of blood cells. The 
generation of reactive oxygen species (ROS) from compromised 
mitochondria not only leads to direct cellular damage but also 
can trigger the activation of both the peripheral (leukocytes) 
and brain resident (microglia) immune pathways, which in turn, 
elaborate various damaging immune mediators and effectors 
including more ROS. This vicious cycle in acute ischemic stroke 
is referred to as cerebral R/I (Figure 1) (10, 11).
The evidence for R/I was previously demonstrated using 
experimental stroke models. A few groups have reported that 
ischemic injury is greater in animals where reperfusion occurs 
[temporary middle cerebral artery occlusion (tMCAO) for 2–3 h] 
compared to animals where there is no reperfusion (pMCAO) 
(12, 13). In a series of experiments where the duration of MCAO 
was varied and compared to pMCAO, tMCAO for less than 2 h 
led to smaller infarct sizes compared to pMCAO (14). Occlusion 
durations of more than 2  h led to paradoxically larger infarct 
volumes. However, direct evidence for R/I is less clear at the clini-
cal level. While a rare “hyperperfusion syndrome” of accelerated 
brain edema and transient clinical worsening following abrupt 
revascularization has been described (15), it is not clear whether 
this results in permanent worsened outcome. Further, the 
neurotoxicity of tPA has been shown in previous studies, where 
endogenous tPA may directly contribute to worsened outcome 
(16). Further, it is quite clear that revascularization after certain 
time windows can worsen outcomes compared to no intervention 
(6) and could be said to represent R/I in humans. Hence, target-
ing aspects of R/I might suggest an opportunity to synergistically 
improve neurological outcome for thrombolysis and/or mechani-
cal embolectomy.
While the concept of R/I as a therapeutic target surrounding 
revascularization, the efficacy of treatment in experimental rep-
erfusion models does not necessarily predict the results of clinical 
trials. A PubMed search for experimental studies covering the 
terms “reperfusion injury, cerebral ischemia, and inflammation” 
revealed that 888 studies have been performed using the tMCAO 
model. However, only one agent (edaravone) has actually been 
transition to the clinical level in Japan. Experimental reperfusion 
models do not fully replicate what happens in clinical stroke. 
Hence some reports argue that experimental reperfusion models 
were inappropriate for clinical translation (17). Regardless, the 
timing of treatment is different for each clinical case. These fac-
tors are major problems that cannot be avoided. However, some 
novel mechanisms associated with R/I have been established in 
over the years by studying experimental models and may suggest 
therapeutic targets which could be studied at the clinical level in 
this new era of recanalization.
In this review, we will focus on the mechanism of R/I in acute 
ischemic stroke and reconsider its treatment, with a focus on proin-
flammatory targets, including some already in use at the clinical level.
iNFLAMMATiON iN STROKe
The poststroke inflammatory response consists of aberrant acti-
vation of glial cells, particularly microglia, and the infiltration of 
peripheral leukocytes, following exposure to molecules contain-
ing damage-associated molecular patterns (DAMPs) released by 
ischemic brain cells (Figure 1) (18–22). DAMPs studied in brain 
ischemia include HMGB-1, purines, nucleotides such as ATP and 
UDP, and nucleic acid fragments (15). DAMPs stimulate immune 
cell production of cytokines/chemokines, adhesion molecules, 
and several immune molecule effectors such as matrix metallo-
proteinases-9 (MMP-9), inducible nitric oxide synthase (iNOS), 
nitric oxide (NO), ROS, and nicotinamide adenine dinucleotide 
phosphate (NADPH) oxidase, all of which lead to exacerbation of 
cerebral ischemic injury (18, 20, 21).
Microglial/Macrophage Activation
Microglia are the brain’s resident immune cell (23) and are 
involved in the modulation of the brain’s inflammatory response. 
Circulating monocytes are also recruited from bloodstream and 
enter brain as macrophage and associated with inflammation (24). 
Once injury occurs, microglia and macrophage are activated and 
release proinflammatory molecules such as cytokines [e.g., tumor 
necrosis factor-α (TNF-α), interleukin-1β [IL-1β], IL-6, and 
interferon-γ (IFN-γ)], chemokines, NO, ROS, MMP-9, glutamate, 
and ATP (25–32). Microglia are immediately activated following 
ischemia, elaborating various immune molecules which set the 
stage for the recruitment of circulating leukocytes (27). Activated 
microglia affects to neuroinflammation as macrophage-like cells 
(33). Macrophages also enter the brain from the circulation as 
early as 24 h after stroke onset. Their numbers in ischemic lesions 
peak within 3–7 days (34) but remain within the lesion for weeks 
to even months (35–39). Phagocytic microglia or infiltrated 
circulating macrophages are thought to remove necrotic debris 
and other potentially damaging substances, paving the way for 
recovery and repair (40).
Interestingly, while activated microglia/macrophage have 
been thought to worsen damage in stroke, they also appear to 
contribute to their protection (35, 41–44). Recent work has now 
shown that activated microglia/macrophage can be classified into 
two broad subpopulations—M1 and M2, with the former being 
proinflammatory and the latter being anti-inflammatory (33, 45). 
Acutely, microglia appear to polarize predominantly to a M1 
FigURe 1 | Ischemia-induced inflammation in association with reperfusion injury. Once brain ischemia occurs, oxygen and glucose supplies are reduced. If ischemia 
occurs for more than a certain time period (likely a few hours, but the precise duration is not well established) and blood flow is restored (reperfusion), worsened 
injury can paradoxically occur to the brain. This is often referred to as reperfusion injury. A major component of reperfusion injury involves subsequent inflammatory 
reactions induced through various mechanisms. Reperfusion leads to the introduction of ROS from oxygenated blood and can stimulate an immune response in the 
ischemic brain. Necrotic, ischemia-injured cells lyse and release their contents into the extracelluar space which can act as ligands for various immune receptors. 
Among these include nucleic acids which are one of many described damage-associated molecular pattern (DAMPs, see text for details). DAMPs can then bind 
TLRs and stimulate several inflammatory responses (microglial activation, overexpression of proinflammatory cytokines, chemokines) which lead to worsened brain 
injury. Inflammatory signaling also causes immune cells to generate more effector molecules such as ROS and iNOS/NO. In the periphery, cytokines and adhesion 
molecules can attract circulating immune cells to the ischemic brain where they infiltrate the damaged tissue and further amplify ischemic injury. Some circulating 
immune cells and platelets can also plug the microvasculature of the ischemic brain and cause secondary reductions in local CBF. In addition to brain cells, these 
inflammatory reactions can also cause damage to brain endothelia causing BBB disruption, edema and hemorrhagic transformation. Thus, the restoration of CBF 
can cause more extensive brain tissue damage. This vicious cycle is often called reperfusion injury. ROS, reactive oxygen species; DAMPs, damage-associated 
molecular patterns; TLR, toll-like receptor; MMPs, matrix metalloproteinases; iNOS, inducible nitric oxide synthase; NO, nitric oxide; BBB, blood–brain barrier; CBF, 
cerebral blood flow.
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phenotype and produce cytokines, ROS, and reactive nitrogen 
species (45). As such, iNOS is the major NOS in immune cells 
that leads to NO generation, and is often used as a M1 marker 
(46). The M1 phenotype is mainly associated with proinflamma-
tory signaling (47). In contrast, the M2 phenotype contributes 
to anti-inflammatory responses as well as recovery and repair 
(45). Cytokines associated with the M2 phenotype include IL-4, 
IL-10, IL-13, IGF-1, and transforming growth factor (TGF)-β 
(33, 45, 48). These cytokines are also important for protection 
from inflammation (33, 48–53). Arginase 1, which competes 
with iNOS and downregulates NO production, is often used as a 
marker for M2 activation (54).
Several innate immune receptors have been studied in rela-
tion to activated microglia and the inflammatory cascade. These 
receptors have in common their ability to activate when stimu-
lated by DAMPs. Purinergic receptors, especially P2X7 and P2Y12, 
were previously reported to modulate microglial activation and 
mediate neurotoxicity (55). Similarly, pharmacologic inhibition 
of P2X7 and P2Y12 reduced brain injury in experimental stroke 
models (55). Other innate immune receptors studied in stroke 
include toll-like receptors (TLRs), transient receptor potential 
melastatin 2, CD36 scavenger receptors, and receptor for 
advanced glycosylation endproducts (RAGE) (56–60).
Astrocyte
Astrocytes also play an important role as the source of various 
inflammatory molecules (61). Activated astrocytes are sometimes 
referred to as “reactive gliosis” after ischemia and have been 
observed 4–24 h after ischemia onset, peaking at around 4 days. 
This state is accompanied by astrocytic upregulation of glial fibril-
lary acidic protein. The resulting glial scar is a consequence of 
reactive cellular processes that consists of activated astrocytes and 
has an important role which leads to both benefit and harm (62). 
While this glial scar acts as a barrier surrounding the ischemic 
lesion, it may also prevent axonal regrowth (63). Further, activated 
astrocytes are directly associated with inflammatory responses 
after ischemia through upregulation of major histocompatibility 
complex and other inflammatory molecules such as cytokines, 
chemokines and iNOS (61). These molecules can exacerbate 
ischemic injury. In contrast, activated astrocytes are also capable 
of developing Th2 (anti-inflammatory) responses, although this 
mechanism has not been reported in ischemia (64). Further, some 
astrocyte derived immune molecules have been shown to have 
contrasting effects in a model of spinal cord injury (65). Thus, the 
modulation of activated astrocytes may be critical in influencing 
the role of inflammation in brain ischemia, although this area of 
investigation is still quite new.
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Leukocyte infiltration
There are very few peripheral leukocytes in uninjured brain, 
but once an ischemic stroke occurs, endothelial cells within the 
cerebral microvasculature are activated and leukocyte infiltra-
tion follows a few hours later (41, 66, 67). This immune cell 
activation and infiltration appears to be more robust following 
tMCAO compared to pMCAO (68). Once infiltrated, leukocytes 
contribute to the worsening of brain damage through similar 
mechanisms as activated microglia (18, 35). In addition, circulat-
ing leukocytes also lead to platelet aggregation through activation 
of the arachidonic acid cascade (i.e., leukotrienes, thromboxane, 
and prostaglandins) (69). This aggregation promotes a prothrom-
botic state and induces a “no-reflow” state which can also further 
compromise ischemic tissue (61, 70). Leukocyte–platelet com-
plexes are formed which causes further damage by plugging the 
microvasculature. Thus, circulating leukocytes worsen ischemic 
injury through direct infiltration into the ischemic brain and by 
obstructing in situ blood flow (61).
Neutrophils
Neutrophils are the first population of leukocytes to appear in 
the acute ischemic brain (71, 72). While they function as any 
other effector immune cell, their significance has been debated. 
Several studies have shown that inhibiting their ability to infil-
trate ischemic brain led to smaller lesion sizes (61). However, 
numbers of neutrophils in the ischemic brain do not appear to 
predict stroke severity (73–75). Further, this strategy has not been 
shown to improve outcomes in stroke patients (76). In addition, 
Enzmann et al. (75) argued that neutrophil infiltration was not 
present in infarcts at an early stage after ischemia. In this study, 
platelet aggregation, sites of increased vessel permeability, and 
sites of enhanced expression of endothelial adhesion molecules 
were also correlated with neutrophils infiltration. Hence, the role 
of neutrophils in stroke is still unclear, particularly since clinical 
studies to inhibit their infiltration were conflicting.
Lymphocytes
Activated T  lymphocytes also appear in ischemic brain tissue 
as early as 24  h after reperfusion, but later than neutrophils 
and before macrophages (77). They act as a modulators of leu-
kocyte and platelet adhesion (78). T  lymphocytes also produce 
inflammatory cytokines such as IL-17 and IFN-γ. CD4+helper, 
CD8+cytotoxic, and γδT cells have been shown to play harmful 
roles in experimental stroke (78, 79). Yilmaz et al. (79) reported 
that the deficiency of CD4+helper/CD8+cytotoxic T  cells led 
to smaller infarct sizes, lower number of adherent leukocytes 
and lymphocytes, and better neurological outcomes following 
tMCAO in mice. γδT  lymphocytes mainly produce IL-17, and 
IL-17 seems to play an important role in the delayed phase of R/I 
(78). Hence, they may be important therapeutic targets. In fact, 
high levels of IL-17 have been documented in human ischemic 
lesions (80). IL-23 also appears to mediate IL-17. Shichita et al. 
(78) showed infarct volume reduction and improvement of 
neurological functions in IL-17/IL-23 KO mice. However, while 
the harmful role of T lymphocytes in brain ischemia was demon-
strated in a tMCAO model and R/I, the same has not been shown 
in pMCAO for unclear reasons (81). Further, T regulatory cells 
(Tregs) seem to play an anti-inflammatory and neuroprotective 
role in ischemic stroke. Tregs interact with other cells to release 
anti-inflammatory cytokines (IL-10 and TGF-β) (24). Liesz et al. 
(82) reported that the depletion of Tregs increased infarct volume 
and worsened of neurological function. Further, anti-CD28 
antibody (CD28SA) was shown to reduce infarct volume and 
improve neurological deficit by increasing numbers of Tregs (83). 
In contrast, Kleinschnitz et al. argued that Tregs could promote IS 
via cerebral microvasculature dysfunction, as Tregs depletion was 
neuroprotective (84). Further, CD28SA contributed to enhanced 
Tregs effects by promoting thromboinflammation Tregs have also 
been reported to inhibit t-PA induced hemorrhagic transforma-
tion (HTf) through regulation of MMP-9 and suggests Tregs as a 
potentially important target in preventing this complication in 
the setting of recombinant tPA use (85). Clearly, Tregs in acute IS 
is complex and more investigation is needed. B lymphocytes also 
contribute to the reduction of inflammation and neurological 
deficits through IL-10 release (86).
In clinical studies, the relationship between lymphocyte num-
bers and poststroke pathology is not clear. Nadareishvili et al. (87) 
reported that high serum lymphocyte counts increased the risk 
of stroke recurrence and mortality. In contrast, Kim et al. (88) 
reported that lower lymphocyte counts were associated with poor 
early neurologic improvement and worse long-term functional 
outcome.
Cytokines/Chemokines
Several cytokines and chemokines are released following ischemic 
brain injury (19, 20). They have been detected in blood, cerebro-
spinal fluid, and infarcted brain regions in both acute ischemic 
stroke patients and experimental animals (20). In microglia, 
distinct molecules are expressed, depending on the cell’s pheno-
type (23, 33). M1 microglia generate proinflammatory cytokines, 
which contribute to the worsening of brain injury (45). The most 
extensively studied of the proinflammatory cytokines include 
IL-1, IL-6, and TNF-α (89). Cytokines from M2 phenotype 
microglia appear to contribute a protective or beneficial effect, 
and are thought to inhibit inflammation and promote tissue 
repair (33, 48–53). Representative anti-inflammatory cytokines 
studied in stroke are IL-4, IL-10, IL-23, and TGF-β1 (33, 45, 48). 
Several chemokines have been studied in stroke models and 
appear to play a variety of roles in cell migration and attraction 
to sites of damage.
Proinflammatory Cytokines
Interleukin-1 is consists of two isoforms IL-1α and IL-1β, which 
are major contributors of acute inflammation in ischemic stroke 
and have been studied as therapeutic targets (90). IL-1 also indi-
rectly affects brain injury through initiating astrogliosis, releasing 
toxic substances [chemokines, vascular cell adhesion molecule 
(VCAM)-1, and intercellular adhesion molecule (ICAM)-1], and 
activating metalloprotenase (MMP)-9 (91–93). Both isoforms 
increase in the first hours of acute ischemic stroke and bind to 
their corresponding receptors (IL-1R1 and IL-1R2) (24, 61, 90). 
Previous studies showed that IL-1β contributed more to ischemic 
pathology rather than IL-1α (93). IL-1β mRNA and protein are 
detected within 1–6 h after ischemia with a biphasic pattern of 
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expression that includes a secondary peak 6–24  h later (94). 
Administration of IL-1β led to the enlargement of infarct size 
(95), whereas the lack of IL-1β was led to smaller infarct size (93). 
Similarly, studies have explored the feasibility of administering its 
endogenous inhibitor, IL-1ra, which seems to improve outcomes 
in experimental models.
Interleukin-6 has also been studied in ischemic stroke, but its 
role has not been clarified. The expression and increase of IL-6 is 
observed as early as 3 h, peaking at 12 h, and remains elevated at 
24 h after onset of brain ischemia (96). IL-6 has been detected in 
plasma and cerebrospinal fluid of stroke patients, and IL-6 immu-
noreactivity has been detected in microglia and cortical neurons 
of ischemic stroke models (96). In patients, IL-6R polymorphisms 
are also related to poor neurological outcomes (97), although IL-6 
polymorphisms did not show an increased risk of ischemic stroke 
(98). To add to the conflicting observations, IL-6-deficient mice 
and mice treated with an IL-6 receptor antagonist mice did not 
have improved outcomes compared to untreated mice (99, 100).
Tumor necrosis factor-α has also been detected in ischemic 
brain (96) and appears largely in microglia as early as 30 min after 
experimental stroke (96). This expression has been observed in 
a variety of other brain cells including neurons and astrocytes. 
Interestingly, TNF-α has been reported to be both neurotoxic 
and neuroprotective in the brain. Yang et al. (101) reported that 
administration of neutralizing antibodies to TNF-α showed 
a protective effect against ischemic injury in tMCAO model. 
In contrast, Bruce et al. (102) reported that ischemic brain injury 
was increased in mice genetically deficient in the TNF receptor. 
Reasons for this discrepancy could be explained by its two differ-
ent surface receptors (TNFR1 and TNFR2) (103). TNF-α exists 
in transmembrane and soluble forms. Soluble TNF-α binds to 
TNFR1 leading to neurotoxic effects, whereas membrane bound 
TNF-α binds to TNFR2 leading to neuroprotective effects (104). 
However, Pradillo et  al. (105) reported that TNFR1 signaling 
pathways led to resistance to ischemic injury through upregula-
tion of TNF-α convertase enzyme and TNFR1. To confuse mat-
ters more, it also appears that the effects of TNF-α induced in 
striatum are neurodegenerative, whereas that in the hippocampus 
is neuroprotective (106).
T cell-releasing proinflammatory cytokines are also important 
in the development of ischemic stroke (77). IFN-γ, IL-17, and 
IL-23 have been studied recently as therapeutic targets (78). 
IL-17 induces TNF-α, IL-1β, and MMP-9 in macrophages and 
expression and IL-23 induces the expression of IL-17 (107, 108). 
As such, IL-17 and IL-23 both contribute to the worsening of 
ischemic injury.
Anti-Inflammatory Cytokines
Interleukin-10 is an anti-inflammatory cytokine mainly pro-
duced by microglia, macrophages, and astrocytes, and has a 
neuroprotective effect in ischemic injury (33, 61). IL-10 acts by 
inhibiting proinflammatory cytokines, such as IL-1β, TNF-α, and 
IFN-γ, and suppresses the expression and activation of cytokine 
receptors (61, 82). Overexpression or administration of IL-10 has 
been reported to reduce brain injury and improve neurological 
outcomes in experimental stroke. Ooboshi et al. (109) reported 
that postischemic gene transfer of IL-10 into the lateral ventricle 
reduced brain infarct size. At the clinical level, lower IL-10 levels 
increased stroke risk (110). Tregs also produce IL-10 (24, 82) and Li 
et al. (111) reported that administration of Tregs reduced immune 
cell infiltration, brain inflammation, and prevented blood–brain 
barrier (BBB) disruption.
Transforming growth factor-β1 is also produced by microglia, 
macrophages, and astrocytes after ischemia and has also been 
shown to protect from ischemic injury (112). Like IL-10, over-
expression or administration of TGF-β1 reduced ischemic lesion 
size and improved neurological outcomes in experimental stroke 
model (113, 114).
Interleukin-4 is another widely studied anti-inflammatory 
cytokine produced by activated Th2 cells, eosinophils, baso-
phils, and mast cells (115). IL-4 signaling is mediated through 
IL-4 receptor α-chain (IL-4Rα) on neutrophils, T  lymphocytes, 
astrocytes, oligodendrocytes, and endothelial cells (116, 117). 
After binding, this complex dimerizes with the common γ-chain 
or IL-13Rα1 which is a closely related cytokine receptor (118). 
This signaling contributes to potent anti-inflammatory responses 
in ischemic brain which include upregulating Arg1, Ym1, found 
in inflammatory zone 1 (FIZZ1), CD206 (mannose receptor), 
chemokine ligand 22 (CCL22), and CD163, which are also M2 
specific markers (117). IL-4 inhibits the release of proinflamma-
tory cytokine genes such as IL-1β, TNF-α, IL-6, and chemokines, 
and the activation of macrophage mannose receptor (119). IL-4 
levels in brain are generally very low, but increase several hours 
after stroke onset (116). Xiong et  al. (51) reported that IL-4 
deficiency exacerbated brain injury and worsened neurological 
outcomes in tMCAO. Further, IL-4 appears to have long-term 
neuroprotective effects after experimental stroke (116). However, 
it bears mentioning that other studies reported that IL-4 was 
associated with proinflammatory responses (120). Pretreatment 
of monocytes and macrophages with IL-4 has also been shown 
to enhance proinflammatory cytokine gene expression such as 
TNF-α, IL1-α, and macrophage-inflammatory protein-2 (121).
Chemokines
Chemokines mediate chemotaxis, including leukocyte migra-
tion (122). They also participate in the pathogenesis of cerebral 
ischemia through their involvement in leukocyte infiltration, 
ROS release, and BBB disruption (24, 61). Based on their struc-
tures, chemokines are divided into four subgroups; CXC, CC, C, 
and CX3C (123). Corresponding receptors include CXCR (1–5), 
CCR (1–9), XCR1, and CX3CR1 (61). Both chemokines and their 
receptors have been explored as potential therapeutic targets 
(24, 123).
Stromal cell-derived factor (SDF)-1 (CXCL12) is a CXC 
chemokine (124). It is produced by bone marrow stromal cells 
and acts as a strong chemoattractant for CD34+ cells, which 
express SDF-1α receptor (CXCR4) (124). SDF-1 α/CXCR4 sign-
aling plays an important role in ischemia-induced inflammation 
via activation and migration of leukocytes (125). Ruscher et al. 
(126) reported that the inhibition of CXCL12 reduced infiltra-
tion of immune cells and Huang et al. (127) also confirmed that 
CXCR4 antagonism led to neurological recovery, suppression of 
proinflammatory cell infiltration, reduction of infarct area, and 
BBB disruption in tMCAO.
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Fractalkine (CX3CL1) is a CX3C chemokine that is mainly 
expressed on neurons and acts through CX3CR1 on microglia 
(128). Fractalkine bound to CX3CR1 leads to expression of pro-
inflammatory cytokines, ROS production, BBB disruption, and 
leukocyte infiltration (24, 128). However, the role of CXC3CL1/
CXC3R1 signaling is still controversial. While Soriano et al. (129) 
reported that fractalkine deficiency reduced infarct volume and 
mortality in tMCAO, Cipriani et  al. (130) showed that admin-
istration of CX3CL1 reduced ischemic injury. Reasons for these 
discrepancies are unclear.
Of the CC chemokines, monocyte chemoattractant protein 
(MCP)-1 (CCL2) and macrophage inflammatory protein-1α 
(CCL-3) have been the most studied and participate in leukocyte 
infiltration (24, 131). CCL2 and CCL3 are mainly expressed 
on astrocytes, microglia, and monocytes, and CC chemokine 
inhibition reduced brain injury (132). CC chemokines also 
lead to expression and secretion of Regulated upon Activation, 
Normal T-cell Expressed, and Secreted, also known as C-C motif 
ligand 5 (CCL5) on T cells (123). CCL5 mediates the migration 
and adhesion of leukocytes through three different types of G 
protein-coupled receptors (CCR1, CCR3, and CCR5). Victoria 
et al. (133) confirmed that CCR5 deficiency led to improvement 
of neurological deficits and reduction of infarct volume against 
R/I. CCL5 also forms a heterodimer with CXCL4 and constitutes 
a CXC subgroup. CXCL4-CCL5 enhances the effect of CCL5, 
which contributes to ischemia-induced inflammation and brain 
injury, against which a CXCL4/CCL5 inhibitor protects (134).
Cell Adhesion Molecules
Cell adhesion molecules (CAMs) are involved in the trafficking 
and recruitment of leukocytes to activated ischemic endothelia in 
stroke. They contribute to the inflammatory response and worsen 
ischemic brain injury (135). CAMs are divided into three sub-
groups; the immunoglobulin superfamily [ICAM-1, 2, VCAM-1, 
platelet-endothelial cell adhesion molecule-1 (PECAM-1), the 
mucosal adhesion (MAdCAM-1), and activated leukocyte cell 
adhesion molecule], selectins [P-selectin (CD62P), E-selectin 
(CD62E), and L-selectin (CD62L)], and integrins (CD11, CD18, 
CD29, and CD49) (20). Following stroke, high levels of CAMs 
are expressed on cerebral endothelium, which lead to the recruit-
ment and rolling of leukocytes and platelets in the cerebral 
microvasculature. When these rolling leukocytes approach acti-
vated endothelium, they adhere firmly to endothelial cells, after 
which transendothelial migration occurs leading to infiltration 
of ischemic brain (20, 61, 66). These processes are also thought 
to be responsible for the “no flow phenomenon” of endothelial 
dysfunction.
Selectins as therapeutic targets have also been studied in the 
past. Goussev et al. (136) showed that administration of anti-P-
selectin antibody reduced ischemic injury and HTf in a stroke 
model. Huang et al. (137) also reported the same for antibodies 
against anti-E-selectin. In contrast, the role of L-selectin, which 
presents on leukocytes and mediates leukocyte transmigration, 
is unclear. When it encounters activated endothelium, it is shed 
from the cell surface. However, it may not influence ischemic and 
I/R injury, as studies to inhibit it have not been shown to improve 
outcome or influence leukocyte infiltration in stroke models (61).
Integrins are distributed on the cell surface and contribute to 
cell–extracellular matrix (ECM) adhesion (138). They exist as 
heterodimers which consist of α and β subunits. The migration 
of leukocytes is regulated by a specific integrin, which associates 
with a common β2 chain (CD18). When leukocytes adhesion 
occurs, integrin CD18 binds to ICAM-1. Several α chains 
[e.g., CD11a (LFA-1) and CD11b (Mac-1)] combine with CD18 
prior to adhesion to ICAM-1. Both Mac-1 deficiency and anti-
body inhibition of this integrin led to decreased stroke size and 
numbers of infiltrated neutrophils (61). In addition to leukocytes, 
monocytes and lymphocytes express other integrins composed 
of the β1 (CD29) and β7 (CD103) subunits. These subunits com-
bine with the α4 integrin (CD49d) and interact with VCAM-1, 
MAdCAM-1, and the subendothelial matrix (61, 139).
Immunoglobulin superfamily members are also cell surface 
glycoproteins, which are expressed on endothelial cells, leuko-
cytes, platelets, fibroblasts, and epithelial cell (20, 61). ICAM-1 
(CD54) exists constitutively at low levels, and it is upregulated 
by cytokines following ischemia (20). Kitagawa et  al. (140) 
and Zhang et  al. (141) reported that ICAM-1 deficiency or 
anti-ICAM-1 therapy reduced ischemic injury and leukocyte 
adhesion. VCAM-1 (CD106) is upregulated by proinflammatory 
cytokines TNF-α and IL-1. Although PECAM-1 (CD31) is not 
upregulated by cytokines, it plays an important role in endothelial 
cell adhesion and leukocytes transmigration (142). Liesz et  al. 
(143) also found that VCAM-1 deficiency reduced T lymphocyte 
infiltration into the brain and reduced infarct volume. Studies 
of CD49d inhibition in two different ischemic stroke models 
(tMCAO and pMCAO) showed that infarct volume was reduced 
and leukocyte infiltration was suppressed (144).
However, the efficacy of antiadhesion molecule strategies has 
not been established at the clinical level. The Enlimomab trial, 
which evaluated the efficacy of an ICAM-1 antibody in acute 
IS patients, showed that was antibody-treated patients actually 
had worsening of neurological function, increased mortality and 
fever compared to the placebo group. The HALT and Acute Stroke 
Therapy by Inhibition of Neutrophils (ASTIN) studies, which 
examined strategies to target the CD11/CD18 leukointegrin were 
both negative, and were stopped early due to lack of efficacy (145).
immune Molecule effectors
Matrix Metalloproteinase
Matrix metalloproteinases are a family of zinc-binding endo-
peptidases responsible for the ECM turnover and digestion 
of proteins (146). A variety of subtypes are classified based on 
structural similarity; collagenases, gelatinases, metalloelastases, 
stromelysins, membrane-type MMPs, and others (147). These 
proteases normally participate in wound healing, bone remod-
eling, angiogenesis and other physiological processes (61). 
However, inflammatory stimuli can lead to the activation of 
MMPs from their inactive proform to their cleaved active form 
through signaling via several proinflammatory cytokines (IL-1β) 
and chemokines (CCL-2, 7, 8, and 13) (148, 149). In stroke, MMPs 
have also been shown to participate in R/I. Activated MMP-2 and 
MMP-9 are known to contribute to the inflammatory response 
in acute ischemic stroke (147, 150). Microglia are a major source 
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of MMPs (61) and activated MMPs have been detected within 
a few hours after ischemia onset and detected even 5 days later 
(61, 147). Activated MMP-2 and MMP-9 lead to the digestion 
of the endothelial basal lamina, including the degradation of 
tight junction proteins. This leads BBB disruption and secondary 
injury, causing brain edema and hemorrhagic transformation 
(151). tPA, which is present endogenously, also contributes to 
BBB and ECM disruption. Through its ability to activate plas-
min, tPA indirectly activates MMPs, especially MMP-9, which 
is expressed by immune cells (151). In the setting of treatment 
with recombinant tPA (rt-PA), this could result in more severe 
BBB disruption and hemorrhage, both feared complications of 
pharmacological thrombolysis. Hence, MMP inhibition may be 
a particularly important means of reducing I/R injury.
Matrix metalloproteinase-9-deficient mice had smaller 
infarcts following tMCAO (152), and chimeric studies showed 
that MMP-9 expressed particularly by leukocytes contributed 
to worsened stroke outcome (153). Clinical studies showed that 
serum MMP-9 levels correlated with stroke severity, with MMP-9 
mRNA as a predictor of poor outcome (154).
Matrix metalloproteinase-2 has similar properties as MMP-9; 
however, its roles in ischemic stroke are still unclear. Previous 
reports showed that MMP-2 deficiency in experimental stroke 
and serum MMP-2 levels in stroke patients did not affect 
ischemic lesion size or stroke severity, respectively (155). Yet, 
MMP-2 activity increases in the later phase of ischemic stroke 
(147) and basal MMP-2 levels were higher in patients with stable 
or recovering symptoms (156). MMP-2 elevations, at least in the 
acute phase of ischemic stroke, might also be associated with 
better clinical outcomes.
Inducible Nitric Oxide Synthase/Nitric oxide
Nitric oxide is synthesized from l-arginine and oxygen through 
nitric oxide synthase (NOS) (157). Three NOS isoforms are 
known: endothelial NOS (eNOS), neuronal NOS (nNOS), 
and iNOS (158). iNOS is increased in immune cells including 
leukocytes, microglia, macrophage, and possibly astrocytes in 
response to proinflammatory stimuli, while eNOS and nNOS 
exist in the vascular endothelium and neurons, respectively (159). 
Damaging effects of NO derived from iNOS have been shown in 
experimental stroke. Iadecola et al. (160) and Zhao et al. (161) 
reported that inhibition or deficiency of iNOS reduced infarct 
size and improved neurological outcomes. High serum levels of 
iNOS have also correlated with a worse outcome (162).
ROS/NADPH Oxidase
While ROS are generated from a variety of sources following 
stroke, immune cells generate ROS as part of their microbicidal 
functions. Several pro-oxidant enzymes exist within immune cells, 
but substantial work pertaining to stroke has centered around 
NADPH oxidase (NOX) (163, 164). NOX is a multicomponent 
enzyme consisting of six subunits within the plasma membrane 
subunits (gp91phox, gp22phox) and cytoplasm (gp47phox, gp67phox, 
gp40phox and Rho family GTPases) (163). After activation, NOX 
is phosphorylated, and the cytoplasmic subunits translocate to 
the membrane and form a complete complex on the cell surface. 
When this occurs, superoxide is generated from oxygen by 
electron transfer from NADPH (163, 165). Different isoforms of 
NOX have been identified, with NOX1, 2, and 4 being described 
in ischemic injury (166–168). In experimental stroke models, 
deficiency of both gp91phox and gp47phox NOX subunits reduced 
lesion size, immune cell activation, and superoxide generation, as 
did pharmacological inhibition with apocynin (169). NOX4 was 
also shown to be a relevant therapeutic target, as its inhibition or 
deletion led to protection (170). These investigators also showed 
that NOX4 was a major source of oxidative stress.
Transcriptional Regulation of inflammation
Several transcription factors have been identified as regulators of 
the ischemic inflammatory response and also represent potential 
targets for intervention.
Nuclear Factor κB (NF-κB)
Nuclear factor-κB is a major transcription factor which con-
tributes the inflammatory response, and has been documented 
in brain ischemia models (171). NF-κB exists as heterodimer 
composed of p65 (RelA) and p50 in the cytosol and bound by its 
inhibitor protein IkB. In the presence of an activating stimulus, 
IkB’s kinase phosphorylates IkB, freeing NF-κB to translocate to 
the nucleus where it binds its consensus sequences to upregulate 
many proinflammatory genes. Since NF-κB also upregulates 
genes involved in cell growth, its role is as a therapeutic target is 
still unclear and data are conflicting. On the one hand, deficiency 
or pharmacological inhibition of NF-κB was protective in some 
experimental stroke models (172, 173), but studies using a dif-
ferent inhibitor (diethyldithiocarbamate) found that this led to 
worsened outcome. Reasons for these discrepancies have been 
explained by the type of inhibitor used or whether NF-κB might 
be protective in some cell population, but damaging in others. 
Thus, treatment strategies specific targeting of NF-κB to differ-
entially inhibit proinflammatory while upregulating prosurvival 
genes may be necessary.
Mitogen-Activated Protein Kinase (MAPK)
Mitogen-activated protein kinase has also been studied in 
ischemia-induced inflammation (174). It is involved in the regu-
lation of inflammatory gene expression and apoptosis (175). Its 
three interlinked MAPK signaling pathways have been assessed 
in experimental stroke models; p38 MAPKs, stress-activated 
protein kinases/c-Jun N-terminal kinases (SAPK/JNK), and 
extracellular signal-regulated kinases (ERKs) (61). In particular, 
p38 MAPK activation has been documented in the production 
and activation of several inflammatory molecules in microglia, 
astrocytes, and neurons (175, 176). p38 MARK activation occurs 
via several kinases: MLK3, MKK3/MKK6, and MKK4. NO 
regulates the activity of p38 MARK through phosphorylation and 
S-nitrosylation. Inhibition of p38 MARK activation by SB239063 
has been shown to protective against ischemic brain injury via 
suppression of proinflammatory cytokine/chemokine expression 
and synaptic dysfunction (177).
Complement System
Complement system also plays crucial roles in association with IS 
and R/I and consists of secreted and membrane-bound proteins 
TAbLe 1 | Neuroprotective agents and therapies for ischemia-induced inflammation and reperfusion injury in experimental stroke models and clinical trials.
Neuroprotective agent/therapy Animal model infarct volume Neurological 
outcome
Clinical trial
Minocycline (192–204) temporary middle cerebral 
artery occlusion (tMCAO) rat
Reduced Improved Better outcome (small trial)
Integrin (205, 206) tMCAO rabbit Reduced – No efficacy
Anti-ICAM-1 antibody (207, 208) tMCAO mice Reduced – No efficacy
Anti-IL-1receptor agonist (95, 209) tMCAO rat Reduced – Better outcome (small trial)
Edaravone (210–216) tMCAO rat Reduced Improved Better outcome
Simvastatin (217) tMCAO rat Reduced Improved No efficacy (combined with tissue 
plasminogen activator)
Rosuvastatin (218) tMCAO rat Reduced Improved –
Pioglitazone (219) tMCAO rat Reduced – –
Sitagliptin (220) tMCAO rat Reduction of inflammatory 
mediators
–
Fingolimod (221–229) tMCAO rat Reduced Improved Better outcome
Natalizumab (230–232) tMCAO rat Reduced Improved Better outcome (small trial)
Cyclosporine A (233, 234) tMCAO rat Reduced Improved No efficacy
Glatiramer (235) tMCAO mice No efficacy No efficacy –
Intravenous immunoglobulin therapy (236) tMCAO mice Reduced Improved –
Hypothermia (237–242) tMCAO rat Reduced Improved Better outcome
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(178). When this system is activated, three major pathways 
are involved in its activation: the classical pathway (CP), the 
alternative pathway (AP), and the lectin pathway (LP). Once 
ischemia occurs, the complement system is activated via both 
of CP and LP (179). This complement cascade contributes to 
microglial activation, leukocyte adhesion and recruitment, pro-
motion of phagocytic system, and direct cellular lysis (178–181). 
Several studies have been performed using experimental stroke 
models. Especially in the LP, mannose-binding lectin (MBL), 
which binds with the natural self-reactive IgM antibody and a 
LP-specific protease called mannan-binding lectin-associated 
serine proteases (MASPs)-2 have been recognized as key players. 
Antibody-deficient (Rag1−/−) or MBL-deficient mice exposed to 
experimental stroke were found to have reduced brain injury 
(182, 183). MASPs-2 antibody treatment also reduced infarct 
volume and improved neurological deficits in a similar model 
(179). In association with C3 cleavage, inhibition of complement 
receptor 2 which binds to C3d, led to the reduction of IgM and 
complement deposition, P-selectin, and neutrophil infiltration in 
experimental stroke (178).
Damage-Associated Molecular Patterns
Recent work has begun to identify factors which trigger the 
inflammatory response in stroke and related insults. Like path-
ogen-associated molecular patterns (PAMPS), DAMPS include 
several molecules elaborated by injured cells which are able to 
bind any number of immune receptors. Some which have been 
identified in stroke and related brain injury models include high 
mobility group box-1, heat shock proteins, peroxiredoxin, nucleic 
acids, purines, and β-amyloid (61, 184). Neurons appear to be 
an early source of DAMPs in stroke. The complement system 
and several immune receptors recognize DAMPs and induce 
inflammation following IS and in association with R/I. Targets of 
DAMPs include several innate immune receptors, and those most 
studied in cerebral ischemic include the TLRs and purinergic 
receptors.
Toll-like receptors are present on the cell surface and act as 
a sensor of the innate immune response. TLR2 and TLR4 have 
been the most studied of these in stroke models (185). Following 
ischemic insults, brain cells elaborate DAMPs which then stimu-
late TLR2 and TLR4 (22, 184). Through TLR signaling, inflam-
matory responses including microglial activation, induction of 
proinflammatory cytokines, neutrophil/lymphocyte infiltration, 
and NF-κB activation lead to brain injury. A few studies have 
shown that deletion or inhibition of these TLRs improve experi-
mental stroke outcome, whereas their overexpression exacerbates 
it (186, 187). However, one report showed that mice lacking TLR2 
had larger infarcts and increased mortality (188) and another 
showed that TLR2 and TLR4 deficiency in microglia failed to 
ameliorate ischemic injury (189).
As mentioned previously (see Microglial/Macrophage 
Activation), purinergic receptors have also been studied in stroke 
models. Purinergic receptors bind purines, including ATP and 
UDP, and when activated, lead to immune cell chemotaxis and 
phagocytosis (190, 191). Deficiency of the P2Y12 purinergic 
receptor led to improved neurological outcome and reduced 
microglial migration (55). Of particular relevance to stroke, the 
P2Y12 purinergic receptor can be inhibited by the commonly 
used antiplatelet drug clopidogrel.
ANTi-iNFLAMMATORY TReATMeNTS
Several treatments to prevent ischemia-induced inflammation 
and modulate immune response have been studied in both experi-
mental stroke and clinical trials (Table 1), which we review here.
Minocycline
Minocycline is a semisynthetic tetracycline antibiotic which has 
pleiotropic actions (243). This agent has been shown to improve 
chronic inflammation in several models of neurological diseases 
including experimental stroke (192). Rodents subjected to focal 
and global cerebral ischemia showed neurological improvement 
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with correlations to anti-inflammatory, antioxidant, and antia-
poptotic effects with a somewhat wide temporal therapeutic 
window of at least 4 h (193–197). In fact, in one study showed 
that delaying minocycline treatment even 4  days post-tMCAO 
and continued for 4  weeks led to improved motor and cogni-
tive functions and reduced microglial activation and improved 
neurogenesis (198). A major mechanism of neuroprotection is 
thought to be due to its ability to suppress microglial activation 
via inhibition of the MAPK p38 pathway and NLRP3 inflam-
masome signaling (194). Minocycline treatment was correlated 
with the reduction of several proinflammatory cytokines, as well 
as ROS and NO (197, 199). Minocycline also improved BBB 
viability and integrity by promoting neurovascular remodeling 
via MMP inhibition (195, 197). Monocyte chemotactic protein-
induced protein1 (MCPIP1), which is expressed in monocytes 
following exposure to MCP-1, has also been shown to be an 
important mediator of minocycline-induced neuroprotection. 
Minocycline upregulated MCPIP1 in neurons and microglia and 
MCPIP1 inhibits expression of proinflammatory cytokines due to 
negative regulation of NF-κB signaling pathways (199).
Minocycline has also been studied in combination therapy. 
For example, minocycline and aspirin led to reduction of ischemic 
injury, brain edema, BBB disruption, and neurological dysfunction 
in diabetic rats subjected to tMCAO (200). MMP-2 and MMP-9 
were both suppressed by treatment, as were cyclooxygenase-2 and 
tPA. In combination with cell based therapy, minocycline induced 
the pleiotropic protein Nrf2, which provided an antioxidant effect 
that protected transplanted neural stem cells in a stroke models 
(201, 202). Normobaric hyperxia plus minocycline also demon-
strated synergistic effects, with greater protection together than 
each intervention alone.
Finally, minocycline has also been studied in a few clinical 
trials. In a small study, oral minocycline contributed to better 
outcomes as measured by lower National Institute of Health 
Stroke Scale [NIHSS] and modified Rankin Scale [mRS] scores, 
and higher Barthel Index [BI] in patients with acute ischemic 
stroke (203). Intravenous minocycline therapy was associated 
with reduced MMP-9 levels in stroke patients (204). Since 
minocycline is already in clinical use for other indications and 
has an acceptable safety profile, it could be considered as an 
adjunctive treatment to pharmacological thrombolysis and/or 
mechanical thrombectomy. Because it already in clinical use for 
other indications, minocycline could conceivably be given to 
acute IS patients.
Fingolimod (FTY720)
FTY720 is a lipophilic immunomodulatory sphingosine-1-phosphate 
(S1P) analog, which is now used for treatment of multiple sclerosis 
and prevents T-lymphocyte egress from lymphoid organs (244). 
FTY720 reduces R/I to the other organs such as kidney, liver, and 
heart in the laboratory (221, 222). Studies in cerebral ischemia 
have similarly shown reduction in I/R injury and improvement in 
neurological function (223). One study even modeled a clinically 
relevant scenario of experimental thromboembolic stroke and 
combination treatment with fingolimod and rt-PA. This study 
found not only improvement in neurological outcome but also 
reduction in HTf (224).
FTY720 is known to act differential S1P receptors (-1 [S1P1], -3 
[S1P3], -4 [S1P4], and -5 receptors [S1P5]) (225). Phosphorylated 
FTY720 mainly binds to lymphocyte S1P1 receptors in neuron 
and contributes to anti-inflammatory effect due to reduction of 
T-lymphocyte infiltration and proinflammatory cytokines (IFN-γ, 
IL-17) (226). S1P1 also plays an important role in enhancing 
BBB integrity (225). Once ischemic stroke occurs, S1P levels 
are increased and S1P-related enzymes are upregulated in the 
injured brain. In experimental stroke, FTY720 is associated with 
activation of prosurvival factors Akt and ERK (226). In addition 
to S1P1, FTY720 was also thought to signal through the S1P3 
receptor (227). In addition to S1P receptor-related mechanisms, 
FTY720 may directly act to suppress microglia/macrophage 
activation and reduce proinflammatory cytokines, neutrophil 
infiltration and downregulate adhesion molecules (e.g., ICAM-1) 
(221, 225). FTY720 appears to have at least two temporal thera-
peutic windows ranging from 1 to 3 or 4 days after ischemia (sup-
pression of microglial activation) and up to 14 days after ischemia 
(suppression of T-lymphocytes infiltration).
However, some studies failed to show any benefit of fingolimod. 
FTY720 treatment in pMCAO did not affect stroke outcome, 
findings that might suggest that any beneficial effect is through 
mechanisms exclusive to R/I (228, 229). Yet another study failed 
to show any benefit when fingolimod was given in combination 
with rt-PA, thus contradicting the results of the above referenced 
investigation (245).
There is some experience with fingolimod at the clinical level. 
In addition to its use in multiple sclerosis where it has been shown 
to improve disease course, FTY720 has been studied in ischemic 
stroke patients. Fu et al. (246) administered FTY720 6–72 h post-
stroke to patients with anterior cerebral circulation syndromes 
for 3 days. They reported that oral FTY720 could be given safely 
and improved neurological recovery at 90  days. FTY720 treat-
ment also decreased microvascular permeability and circulating 
lymphocyte counts. While clinical experience is still limited at 
this point, it may be worthwhile to pursue larger trials.
Neutrophil and Cytokine inhibition
Antineutrophil interventions to prevent neutrophil infiltration, 
trafficking and/or activation have been studied at both the labora-
tory and clinical levels. Several reports of neutrophil depletion led 
to reduced infarct volume and infiltrated brain neutrophil counts 
(66, 71–73). Pharmacologically blocking leukocyte adhesion and 
migration into ischemic brain were performed in several experi-
mental models with salutary results (102, 205) that led to the 
design of a few clinical studies using antibodies against adhesion 
molecules such as ICAM-1 and CD11/CD18 or by administer-
ing neutrophil inhibiting factor in the ASTIN trial (76, 206). 
However, none these studies were efficacious. In fact, the study 
of an anti-ICAM-1 antibody not only showed lack of benefit but 
also showed that this treatment made patients worse (207, 208).
Cytokine inhibiting strategies have also been studied at the 
clinical level. In one phase II trial, human recombinant IL-1 
receptor antagonist (IL-1Ra), IL-1’s endogenous inhibitor, 
was studied (209). In this trial, inflammatory molecules were 
decreased among IL-1Ra-treated patients and these patients also 
had improved neurological function and smaller infarct volumes.
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Hypothermia
Hypothermia (HT) has been lauded as the prototypical neuro-
protectant, and clinical studies have shown that mild to moderate 
cooling improves neurological outcomes following cardiac arrest 
and neonatal hypoxia ischemia (237). While it has yet to be 
shown as improving in clinical stroke outcome, several labora-
tory studies have shown it to be robustly protective. Particularly 
in tMCAO, HT appears to be robust across several laboratories 
and experimental models (238, 239). One mechanism underly-
ing its beneficial effect is that therapeutic cooling seems to have 
remarkable effects on suppressing inflammation (240). Reduction 
of inflammatory molecules by HT therapy has been shown by 
several groups, including proinflammatory cytokines (IL-1β, 
TNF-α, IL-6), MMPs (MMP-9, MMP-2), and NF-κB (241). 
HT has been suggested as an adjunctive treatment in ischemic 
stroke including I/R injury (242, 247). Relevant to cotreatment 
with rt-PA, HT has been shown in the laboratory to extend the 
therapeutic time-window of other neuroprotectants, sometimes 
extending the therapeutic window from 2 h to over 2 months, 
in some cases (242). Combination therapy with HT and rt-PA 
at the experimental level has revealed varying results (248), but 
such a combination did not appear to increase HTf or increase 
mortality (249).
At the clinical level, the ICTuS2 study examined HT in acute 
stroke and included patients who were eligible for treatment 
with rt-PA (250). This study showed that both HT and HT plus 
rt-PA were both safe and feasible, but cooling increased the risk 
of pneumonia. In a different study, Hong et al. (247) reported in 
a small study that mild HT therapy (temperatures of 34.5°C) for 
48 h followed by 48 h of rewarming led to reduction of HTf and 
brain edema and better clinical outcomes.
Others
Edaravone is an antioxidant and ROS scavenger marketed as 
a neurovascular protective agent (210). Okamura et  al. (211) 
reported that edaravone reduced infarct volume, brain edema, 
and HTf 24 h after stroke in tMCAO in rats. This was also cor-
related with reduction in inflammatory molecules, proinflamma-
tory cytokines (IL-1β and IL-6), chemokines (fractalkine), and 
MMP-9 (210). At the clinical level, neurological function includ-
ing NIHSS and BI was improved and several adverse events (HTf, 
pulmonary infection, stroke recurrence, and seizures) were also 
reduced by edaravone (212, 213). Edaravone is already approved 
for the treatment of ischemic stroke patients who present within 
24 h of the onset of symptoms in Japan and other countries, but 
not the United States (251).
3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibi-
tors (statins) are used for treatment of dyslipidemia and are nearly 
routinely prescribed for secondary prevention of stroke (252). 
Statins have been also studied as neuroprotectants in experimen-
tal stroke (253). Statins have been correlated with upregulation of 
eNOS, inhibition of ROS-induced lipid peroxidation, reduction 
of superoxide as well as anti-inflammatory effects (254). A variety 
of statins have been shown to reduce infarct volume and improve 
neurological deficit in experimental stroke (217). Rosuvastatin 
was also shown to reduce R/I by inhibiting oxidative stress and 
inflammatory responses such as reducing superoxide and NOX, 
inhibiting microglial activation, and downregulating of inflam-
matory molecules (NF-κB, iNOS) (218). In clinical studies, 
Simvastatin has been shown to reduce subsequent strokes and 
improve neurological function, but efficacy has not been shown 
in combination with tPA (255, 256).
Several antidiabetic drugs have been shown to have a neuro-
protective effect. Kumari et al. (257) reported that treatment with 
peroxisome proliferator-activated receptor γ (PPARγ) agonist 
attenuated infarct volume and reduced inflammatory responses in 
experimental stroke. Generally, PPARγ activation in monocyte-
derived macrophage has been thought to influence macrophage 
polarization (258). It also affects ischemia-induced inflammation 
and HTf (257). Hence, PPARγ agonists act not only to decrease 
serum glucose levels but also to decrease inflammation. Further, 
the PPARγ agonist pioglitazone not only protected from tMCAO 
but also was associated with antioxidant and antiapoptotic effects 
in addition to anti-inflammatory effects in diabetic rats subjected 
to tMCAO (219). PPARγ agonists have pleiotropic effects against 
ischemia/R/I, as do dipeptidyl peptidase-4 inhibitors. In a recent 
study of diabetic rats subjected to experimental stroke, sitagliptin 
administration give before I/R was shown to suppress NF-κB sign-
aling (220). In parallel, it was also shown to be anti-inflammatory, 
antioxidant, and antiapoptotic.
Other immunosuppressive agents used for inflammatory 
diseases have been also evaluated for anti-inflammatory and 
neuroprotective effects in ischemic stroke. Natalizumab, a 
humanized monoclonal antibody to CD49d, has been used for 
treatment of multiple sclerosis. Similar approaches have also 
been studied in acute ischemic stroke (230). Using a related 
antibody, Relton et  al. (231) treated rats subjected to tMCAO 
with antibody to the CD49d into and showed that it reduced 
infarct volume and improved neurological deficits. Treatment 
also led to reduction of lymphocyte infiltration and VCAM-1 
upregulation. However, other studies did not show efficacy using 
this approach. The ACTION clinical trial explored safety and 
efficacy of natalizumab in stroke (232). Natalizumab did not 
affect infarct volume or neurological outcomes (mRS and BI) 
at 90  days; thus, it seems unlikely that natalizumab might be 
further developed for this indication. There are also side effects 
occasionally seen in patients with multiple sclerosis treated with 
this agent. Glatiramer is another compound used in the treatment 
of MS (259). Its anti-inflammatory mechanism is still unclear, 
but it appears to inhibit Th1 proinflammatory cytokines, while 
inducing Th2/Treg activation. Kraft et al. (235) studied glatiramer 
in an experimental stroke model. While microglial activation 
and proinflammatory cytokine generation were suppressed, it 
failed to reduce ischemic lesion volume and neurological defi-
cits. Cyclosporine A, a calcineurin inhibitor used for variety of 
immune diseases, in stroke models led to the reduction of infarct 
size and inflammation through the suppression of cytokines, 
T cell activation, and ROS production, but failed to show efficacy 
in clinical trials (233, 234). Finally, intravenous immunoglobulin 
(IVIG) therapy has been shown to have neuroprotective and 
anti-inflammatory effects in ischemic stroke models by modulat-
ing the TLRs and MARK pathways (236). While IVIG is used 
routinely at the clinical level for other indications, it has yet to be 
studied in stroke patients.
TAbLe 2 | Combined therapy with acute recanalization against ischemia-induced inflammation and reperfusion injury in experimental stroke models and clinical trials.
Neuroprotective agent/therapy Animal model infarct 
volume
Neurological 
outcome
Hemorrhagic 
transformation
Clinical trial
Edaravon (214–216) – – – – Better outcome (with thrombolysis  
and thrombectomy)
Minocycline (260–262) temporary middle cerebral artery 
occlusion (tMCAO) rat
Reduced Improved Reduced Only safety (with thrombolysis)
Progranulin (263) tMCAO rat Reduced Improved Reduced –
Granulocyte-colony stimulating  
factor (264)
tMCAO rat Reduced Improved Reduced –
Fingolimod (265) tMCAO mice – Not improved – Better outcome (with thrombolysis, 
small trial)
Hypothermia (247–250, 266) – – – – Only safety (with thrombolysis and 
thrombectomy)
11
Mizuma and Yenari Anti-Inflammatory Treatment of Reperfusion Injury
Frontiers in Neurology | www.frontiersin.org September 2017 | Volume 8 | Article 467
ANTi-iNFLAMMATORY TReATMeNT 
COMbiNeD wiTH ACUTe 
RevASCULARiZATiON
Recent studies have demonstrated the efficacy of anti-inflammatory 
treatments in combination with rt-PA in experimental stroke 
models. A few clinical studies have similarly focused on com-
bined endovascular treatment (EVT) with anti-inflammatory 
agents (Table 2).
Pharmacological Thrombolysis
The benefit of rt-PA therapy has been established in clinical trials 
(1, 2) but its therapeutic time-window is limited to 3–4.5 h from 
symptoms onset (267). Thus, patients who can receive rt-PA ther-
apy are still limited (3.4–5.2% of all patients with acute ischemic 
stroke) and this is largely due to the risk of R/I, particularly the 
complication of cerebral hemorrhage which can worsen outcome 
and increase mortality (268). tPA is a serine protease and can thus 
promote ECM damage which can lead to HTf (269). Hence, com-
bined therapy with agents that suppress inflammatory molecules, 
thus preventing BBB disruption and downstream effects such as 
edema and hemorrhage seem viable approaches.
As described in section “Others,” edaravone is generally used 
for acute IS treatment. Combination treatment with edaravone 
and rt-PA is also already used at the clinical level in Japan. The 
PROTECT4.5 trial compared rt-PA with rt-PA plus edaravone in 
acute ischemic stroke patients within 4.5 h after symptom onset. 
This study showed that combination therapy accelerated recanali-
zation and reduced the incidence of cerebral hemorrhage (214). 
The YAMATO study was then carried out to determine whether 
early (vs. late) edaravone infusion promoted early recanalization 
and reduced complications, but failed to show any difference in 
outcome with either paradigm (215).
Combination treatment with rt-PA and hypothermia has been 
also studied both in the lab and at the clinical level, as described in 
section “Hypothermia.” Tang et al. (249) reported that rt-PA plus 
HT reduced brain hemorrhage, BBB disruption in mice exposed 
to tMCAO. They also showed that HT reduced endogeneous tPA 
expression. In a clinical trial [Reperfusion and Cooling in Cerebral 
Acute Ischemia (ReCCLAIM)], Horn et al. (270) showed that HT 
could be carried out safely after tPA therapy in patients with large 
infarcts. This study also suggested that this approach could reduce 
R/I, as outcomes were improved compared to stroke patients who 
did not received HT.
While minocycline did not affect rt-PA’s fibrinolytic activity 
and clot lysis when given in combination in an experimental stroke 
model (260). Fan et al. (261) reported that the combination therapy 
of rt-PA with minocycline was effective in hyperglycemia/type 1 
diabetes rats subjected to focal cerebral ischemia. In this study, 
they showed that neutrophil infiltration, microglia activation, 
MMP-9 activity and tight junction protein claudin-5 degradation 
was reduced with combination therapy, compared to rt-PA alone. 
Minocycline is expected to reduce acute inflammatory cascades 
stimulated by thrombolysis. Kohler et al. (262) demonstrated the 
safety of this combination therapy in a pilot clinical study; how-
ever, efficacy in this small study could not be demonstrated, thus, 
emphasizing the need for future a larger clinical trial.
Progranulin (PGRN), a growth factor induced in the brain via 
estrogen, may prove to be a novel adjunctive treatment to rt-PA 
(271.) PGRN has been also reported to inhibit inflammatory 
reactions in stroke models. In tMCAO, PGRN increases especially 
within microglia and vascular endothelial cells 24–72 h after rep-
erfusion (263). PGRN is thought to contribute anti-inflammatory 
and vaso-protective properties. PGRN knockout mice subjected 
to stroke had decreasing IL-10 levels with increasing VEGF levels 
compared to wildtype (263). Combination therapy with rt-PA and 
PGRN was beneficial in a stroke model where it not only reduced 
infarct size, it also reduced complications of R/I such as brain 
edema and hemorrhage, while improving neurological functions.
Granulocyte-colony stimulating factor (G-CSF) is thought to 
provide neuroprotection due to its anti-inflammatory effect (272). 
dela Peña et al. (264) reported that combined therapy with rt-PA 
and G-CSF reduced HTf and improved of neurological function 
24 h after tMCAO rats, compared with rats receiving only rt-PA. 
G-CSF may also be expected to enhance endothelial cell survival 
and reduce their activation; thus, this combination may prevent 
BBB disruption and reduce HTf. Although G-CSF therapy in 
ischemic stroke patients has not been shown to be efficacious, 
its safety was proven for use in other diseases (273, 274). Future 
studies should focus on combination therapy of G-CSF and rt-PA.
Fingolimod has also been studied in combination with 
rt-PA. A pilot study showed that this combination was safe and 
had a possibility to reduced infarct volume, hemorrhage, and 
TAbLe 3 | Recent on going clinical trials of combined therapy with acute recanalization against ischemia-induced inflammation and reperfusion injury.
Trials 
(neuroprotective 
agent/therapy)
Study design Patients number Treatments end point
RHAPSODY 
(3K3A-APC)
Randomized, 
double-blined 
study
n = 110 (age 18–90 years 
and NIHSS ≥ 5)
5 doses (120, 240, 360, 540 µg, and placebo) 
with rt-PA and/or EVT
Safety, pharmacokinetics, and preliminary 
efficacy of multiple ascending doses
STARS07 (Simvastatin) Double-blind, 
randomized, 
controlled study
n = 340 (age over 18 years) Combination of simvastatin (started within 12 h 
from onset) plus rt-PA
Safety and efficacy
SEATIS (Atorvastatin) Randomized, 
open label study
n = 256 (age over 18 years 
and mRS before onset less 
than 2)
2 different atorvastatin doses (80 and 20 mg) 
within 24 h after intravenous rt-PA for at least 
2 weeks
Safety and efficacy (NIHSS, mRS, 
mortality, hemorrhagic complications, 
and recurrence)
ReCCLAIM-II 
(hypothermia)
Randomized, 
open label study
n = 85 (age ≥18, 
≤79 years, ASPECTS 5–10, 
NIHSS 14–29, mRS of 2 
before onset)
Reducing body temperture (mild hypothermia of 
33°) with acute revascularization (rt-PA and EVT), 
compared to normothermia group
Efficacy (hemorrhage conversion, 
hyperintense acute reperfusion marker, 
NIHSS, and mRS), safety (adverse 
events)
rt-PA, recombinant tissue plasminogen activator; EVT, endovascular treatment; NIHSS, National Institute of Health Stroke Scale; mRS, modified Rankin Scale; ASPECTS, Alberta 
Stroke Programme Early CT Score.
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neurological deficit in acute stroke patients (265). In addition to 
fingolimod’s anti-inflammatory effects, it combination with rt-PA 
may also prevent BBB disruption, thus reducing hemorrhage risk.
endovascular Treatment
Recent randomized controlled trials have shown the efficacy of 
EVT within 4.5–12 h after the onset of ischemic stroke (3). The 
stent retriever appears to be particularly effective and safer than 
earlier devices. However, the rate of good clinical outcomes by EVT 
is still limited and adjunctive neuroprotective/anti-inflammatory 
therapy may be desirable in order to reduce complications, likely 
results of R/I. Edaravone is already used in combination with 
EVT in Japan. The RESCUE Japan Registry analyzed the efficacy 
of edaravone in patients with acute cerebral large vessel occlusion 
(216). Edaravone was found to be more effective for the patients 
treated with IV rt-PA than EVT, although the reasons for differ-
ence were unclear.
Hypothermia has been used together with EVT. Chen et al. 
(266) reported that selective brain cooling by intra-arterial 
infusion of cold saline during endovascular recanalization was 
feasible and safe; however, this study did not assess efficacy.
Ongoing Trials
There are now several clinical trials evaluating the safety and efficacy 
of the combined therapy against ischemia-induced inflammation 
and R/I (Table 3). Activated protein C (APC) is an endogenous serine 
protease which has been detected in both neurons and endothelial 
cells (275). APC can suppress microglial activation and leukocyte 
infiltration via the suppression of NF-κB and proinflammatory 
cytokines and adhesion molecules. APC also activates a family of 
G-protein coupled protease-activated receptor1 and prevents BBB 
disruption (276). Thus, APC may be a novel adjunctive therapy to 
EVT because of its anti-inflammatory and BBB stabilizing proper-
ties. The “Safety Evaluation of 3K3A-APC in Ischemic Stroke 
(RHAPSODY)” trial (NCT02222714) which studies the safety and 
efficacy of adjunctive APC with rt-PA, mechanical thrombectomy, 
or both is ongoing (276).
In preclinical studies, statins have been shown to have neu-
roprotective properties through their ability to upregulate eNOS 
(277). Now, there are a few clinical trials to evaluate their efficacy 
in combination with reperfusion strategies. “Stroke Treatment 
with Acute Reperfusion and Simvastatin (STARS07)” trial and 
“The Safety and Efficacy Study of High Dose Atorvastatin after 
Thrombolytic Treatment in Acute Ischemic Stroke (SEATIS)” 
trial (NCT02452502) are undergoing to evaluate the efficacy 
(mortality, recurrence, ischemic lesion volume, HTf, NIHSS, BI, 
and mRS) and safety.
There is also another clinical trial in progress to study neuro-
protective therapy in association with acute recanalization against 
ischemia-induced inflammation and R/I. The “ReCCLAIM-II” 
trial (NCT02411877) compares mild hypothermia to normo-
thermia in patients treated with rt-PA and/or EVT and evaluates 
its effect on neurological efficacy, hemorrhagic conversion, and 
imaging markers of R/I.
CONCLUSiON
Inflammation and R/I following ischemic stroke can worsen 
outcome, and this issue becomes particularly important now that 
there are two broad categories of effective acute revascularization 
treatments. In this review, we focused mainly on inflammatory 
mechanisms and targets to prevent R/I. In reviewing the literature, 
many experimental studies did not necessarily focus on reperfu-
sion as a target, but inflammation modulating interventions for 
neuroprotection. Similarly, the many failed clinical stroke studies 
of neuroprotection were carried out before these treatments were 
approved. There are certainly differences between clinical trials and 
experimental models regarding the mechanisms of reperfusion (or 
lack of reperfusion in early clinical studies) and the alignment or 
misalignment of treatment timing. However, recent progress in 
acute revascularization at the clinical level open the possibility 
of revisiting neuroprotectants to further improve outcomes in a 
synergistic manner. As we are now in the age of restoring CBF, 
it seems worthwhile to address these neuroprotective treatments 
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once again. Perhaps combination therapies with anti-inflammatory 
treatments given to coincide with the onset of reperfusion should 
be the focus of future laboratory and clinical studies with purpose of 
determining whether adjunctive treatment may reduce complica-
tions, further improve neurological outcomes and even determine 
whether the time windows for intervention could be lengthened.
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